-
Tytuł:
-
Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial.
-
Autorzy:
-
Kawahara T; Clinical Research Promotion Center, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. .
Taira N; Breast and Endocrine Surgery Department, Okayama University Hospital, Okayama, Japan.
Shiroiwa T; Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Wako, Japan.
Hagiwara Y; Department of Biostatistics, Division of Health Sciences and Nursing, The University of Tokyo, Tokyo, Japan.
Fukuda T; Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Wako, Japan.
Uemura Y; Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Mukai H; Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
-
Źródło:
-
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation [Qual Life Res] 2022 Jun; Vol. 31 (6), pp. 1829-1836. Date of Electronic Publication: 2022 Jan 04.
-
Typ publikacji:
-
Journal Article; Randomized Controlled Trial
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2005- : Netherlands : Springer Netherlands
Original Publication: Oxford, UK : Rapid Communications of Oxford, Ltd, c1992-
-
MeSH Terms:
-
Breast Neoplasms*
Quality of Life*/psychology
Female ; Humans ; Research Design ; Surveys and Questionnaires
-
References:
-
Am J Clin Oncol. 1982 Dec;5(6):649-55. (PMID: 7165009)
J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32. (PMID: 19920223)
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. (PMID: 8433390)
COPD. 2005 Mar;2(1):63-7. (PMID: 17136964)
BMJ Open. 2018 Jan 10;8(1):e019117. (PMID: 29326191)
Br J Cancer. 2021 Oct;125(9):1217-1225. (PMID: 34480096)
Eur J Cancer. 2012 Jul;48(11):1713-21. (PMID: 22418017)
Lancet. 2017 Mar 18;389(10074):1134-1150. (PMID: 27865536)
N Engl J Med. 2010 Mar 11;362(10):865-9. (PMID: 20220181)
Qual Life Res. 2017 Aug;26(8):2067-2078. (PMID: 28343350)
J Clin Epidemiol. 2008 Feb;61(2):102-9. (PMID: 18177782)
J Clin Oncol. 1998 Jan;16(1):139-44. (PMID: 9440735)
BMJ. 2020 Jun 4;369:m1714. (PMID: 32499297)
JNCI Cancer Spectr. 2019 Jun 04;3(3):pkz037. (PMID: 32328553)
Qual Life Res. 1999 Jun;8(4):311-7. (PMID: 10472163)
BMC Cancer. 2013 Mar 28;13:165. (PMID: 23537330)
Support Care Cancer. 2011 Nov;19(11):1753-60. (PMID: 20886240)
J Clin Oncol. 2011 Jan 1;29(1):89-96. (PMID: 21098316)
J Clin Oncol. 2009 Mar 20;27(9):1368-74. (PMID: 19204202)
Qual Life Res. 2018 Apr;27(4):1089-1098. (PMID: 29188483)
Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):171-84. (PMID: 21476819)
JAMA. 2019 Jan 22;321(3):288-300. (PMID: 30667505)
Health Serv Res. 2005 Apr;40(2):593-7. (PMID: 15762909)
J Clin Oncol. 1995 May;13(5):1249-54. (PMID: 7738629)
Ann Oncol. 2011 Sep;22(9):2107-2112. (PMID: 21324954)
-
Contributed Indexing:
-
Keywords: Anchoring; EORTC QLQ-C30; Health-related quality of life; Minimal important difference; Patient-reported outcomes
-
Entry Date(s):
-
Date Created: 20220104 Date Completed: 20220517 Latest Revision: 20220716
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC9098551
-
DOI:
-
10.1007/s11136-021-03074-y
-
PMID:
-
34982354
-
Purpose: To establish minimal important differences (MIDs) for the European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 (EORTC QLQ-C30) in patients with metastatic breast cancer.
Methods: The dataset was obtained from the SELECT BC-CONFIRM randomized clinical trial. Anchors obtained from patients (transition items) and clinicians (performance status) were used for anchor-based methods. Anchors obtained through 6 months after starting treatment were used for this analysis. Correlation coefficients of anchor and change in QLQ-C30 and effect size were used to qualify for estimating MIDs. Mean change method and generalized estimating equation were applied to estimate MIDs. Distribution-based methods were used for comparison.
Results: We analyzed a dataset of 154 metastatic breast cancer patients. MIDs were estimated in 8 of 15 scales of QLQ-C30. Estimated MIDs for within-group improvement varied from 7 to 15 and those for deterioration varied from - 7 to - 17. Estimated MIDs for between-group improvement varied from 5 to 11 and those for deterioration varied from - 5 to - 8 across QLQ-C30 scales. Patient-reported anchors were more susceptible to early changes in health status than clinician-reported anchors.
Conclusion: We provided the MIDs of the QLQ-C30 using both patient- and clinicians-reported anchors measured in a randomized trial of Japanese patients with metastatic breast cancer. We recommend patient-reported anchors for anchor-based estimation of MID. Our results can aid patients and clinicians, as well as researchers, in the interpretation of QLQ-C30.
(© 2022. The Author(s).)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.